News
-
-
PRESS RELEASE
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides, Inc. elaborates on its lead broad-spectrum antiviral drug candidate NV-387, poised to revolutionize viral disease treatment. Plans include Phase II studies for RSV and market expansion -
-
-
PRESS RELEASE
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
NanoViricides, Inc. comments on the potential of ultra-broad-spectrum antiviral NV-387 against bird flu H5N1 viruses. The company's drug candidate shows promising results in lethal animal model studies -
-
-
PRESS RELEASE
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
NanoViricides, Inc. reports positive results of NV-387 in protecting lungs from damage in influenza virus infection. NV-387 treatment showed reduced lung infiltration, cell death, mucus load, and increased survival -
-
